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Abstract
This study evaluated effects of differing gel volumes on pharmacokinetics (PK). IQB4012, a gel 
containing the non-nucleoside reverse transcriptase inhibitor IQP-0528 and tenofovir (TFV), was 
applied to the pigtailed macaque vagina and rectum. Vaginal gel volumes (1% loading of both 
drugs) were 0.5 or 1.5 ml; following wash-out, 1 or 4 ml of gel were then applied rectally. Blood, 
vaginal, and rectal fluids were collected at 0, 2, 4, and 24 h. Vaginal and rectal tissue biopsies were 
collected at 4 and 24 h. There were no statistically significant differences in concentrations for 
either drug between gel volumes within compartments at matched time points. After vaginal gel 
application, median IQP-0528 concentrations were ~ 104–105 ng/g, 105–106 ng/ml, and 103–105 
ng/ml in vaginal tissues, vaginal fluids, and rectal fluids, respectively (over 24 h). Median vaginal 
TFV concentrations were 1–2 logs lower than IQP-0528 levels at matched time points. After rectal 
gel application, median IQP-0528 and TFV concentrations in rectal fluids were ~ 103–105 ng/ml 
and ~ 102–103 ng/ml, respectively. Concentrations of both drugs sampled in rectal tissues were 
low (~ 101–103 ng/g). For 1 ml gel, half of sampled rectal tissues had undetectable concentrations 
of either drug, and over half of sampled rectal fluids had undetectable TFV concentrations. These 
results indicate differences in drug delivery between the vaginal and rectal compartments, and that 
James M. Smith ajo9@cdc.gov. 
Conflict of interest Lara E. Pereira, Tyana Singletary, Amy Martin, Chuong T. Dinh, Angela Holder, and Janet McNicholl declare no 
conflicts of interest. Karen W. Buckheit, Robert W. Buckheit, Jr., and Anthony S. Ham are employed by ImQuest Biosciences and 
received funding from NIH grant # 5U19AI101961 and declare no conflicts of interest. David F. Katz and James M. Smith received 
funding from NIH grant # 5U19AI101961 and declare no conflicts of interest.
Publisher's Disclaimer: Disclaimer The content is solely the responsibility of the authors and does not necessarily represent the 
official views of the National Institutes of Health. The findings and conclusions in this report are those of the authors and do not 
necessarily represent the views of the Centers for Disease Control and Prevention.
HHS Public Access
Author manuscript
Drug Deliv Transl Res. Author manuscript; available in PMC 2019 August 27.
Published in final edited form as:
Drug Deliv Transl Res. 2018 October ; 8(5): 1180–1190. doi:10.1007/s13346-018-0538-0.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
smaller vaginal gel volumes may not significantly compromise microbicide PK and prophylactic 
potential. However, effects of rectal gel volume on PK for both drugs were less definitive.
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Introduction
Among the HIV preexposure prophylaxis (PrEP) modalities in development today, 
microbicide gels remain a significant arm of the antiretroviral (ARV)-based prevention 
pipeline. Although oral PrEP in the form of once-daily Truvada® (emtricitabine and 
tenofovir disoproxil fumarate) is now FDA approved in the USA [1] and has been shown to 
be effective at preventing HIV acquisition by 44–86% among various demographics [2–8] 
particularly when adherence is high, other biomedical prevention tools are also being 
developed to expand affordable and reliable options for at-risk populations. Alternative PrEP 
methods such as 30–90-day intravaginal rings, long-acting injectables, and on-demand 
products containing one or more ARVs are under research and development, to broaden 
users’ choices and to help circumvent issues related to product adherence, potential long-
term toxicity, accessibility, and/or cost concerns that can be associated with oral PrEP [4, 9–
13].
Microbicide gels are intended to be an on-demand option for men and women who engage 
in vaginal and/or receptive anal intercourse (RAI). By coating the vaginal and rectal mucosa, 
they deliver drug directly down into the tissue, through which it migrates to infectible host 
cells along the length of the vaginal and rectal canals that may be exposed to semen [14]. 
They may also serve as physical barriers to HIV migration into the tissue [15, 16]. However, 
despite extensive studies of the vaginal gels, research on rectal gels has proceeded at a 
slower rate, and safe and efficacious rectal microbicide gels are still in the early stages of 
development [17, 18]. Extension and application of our knowledge of vaginal gels to rectal 
microbicide gels must address biological and behavioral challenges. Hyperosmolar vaginal 
gel formulations or personal lubricants are deemed unsuitable for rectal use due to epithelial 
damage and potentially increased risk of infection [19–21]. Vaginal gels as a PrEP modality 
in women have had low efficacy rates to date, for multiple reasons [4, 22–27]. Recent 
findings point to vaginal microflora as a contributing factor, with potential effects on genital 
inflammation, and ARV uptake and/or stability in vaginal tissues after gel application, but 
further studies of this phenomenon are needed [28–31]. A pattern that does clearly emerge 
from these clinical trials is behavior-based: low adherence is cited as a common factor across 
trials [4, 22, 25, 26, 32]. In light of these findings, emphasis is increasingly placed on 
participants’ personal experiences and preferences in an effort to understand and overcome 
barriers associated with poor adherence. Studies have revealed product-related issues such as 
gel leakage and messiness, as well as undesirable effects on intercourse [32–38]. 
Recommended microbicide gel volumes for vaginal application have been typically 4–5 ml 
[4, 7, 22, 25, 26], and acceptability studies involving rectal gels have evaluated volumes 
ranging from 1.5 to 35 ml [39–44]. While smaller gel volumes might address some user 
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concerns regarding gel leakage, it is unclear whether these will achieve adequate gel 
distribution within the vaginal canal, and efficacious drug levels in vivo to protect against 
HIV infection. However, mathematical models evaluating the effects of gel volume on 
vaginal spreading and consequent mucosal drug delivery have predicted that smaller 
volumes may provide nearly equivalent drug delivery while reducing gel leakage [14].
While modeling and imaging studies are valuable for guiding microbicide gel design and 
use, the experimental in vivo pharmacokinetic (PK) implications of variable gel volumes 
have not previously been evaluated. Using reduced gel volumes is also motivated by the 
prior behavioral studies. We have previously described PK profiles of a dual chamber gel, 
IQB3002, which contains 1% of the NNRTI IQP-0528, a small molecule pyrimidinedione 
that inhibits a number of HIV strains at low EC50 concentrations [45, 46]. The gels’ 
properties, particularly its low osmolality, are specifically formulated for safe application in 
both the vaginal and rectal compartments [47, 48]. Preliminary study of vaginal application 
in female rhesus macaques showed that IQP-0528 concentrations achieved in vaginal tissues 
and fluids were several orders of magnitude above the in vitro EC50 value [45]. Ex vivo 
virus infection assays further demonstrated that human peripheral blood mononuclear cells 
(PBMC) were protected from HIV-1 challenge when co-cultured with vaginal tissue biopsies 
from the gel-treated macaques [45]. Importantly, this level of protection was achieved with a 
reduced vaginal dose of 1.5 ml. That volume was allometrically scaled down versus a typical 
4-ml clinically applied volume in humans via the ratio of approximate surface area of the 
rhesus macaque vagina to that in women. Collectively, our findings prompted further 
investigation of effects of gel volume in microbicide PK evaluations, for both rectal and 
vaginal gels.
The current study extends our previous work and evaluates PK following application of four 
different volumes of a related IQP-0528 gel, IQB4012, in female pigtailed macaques (PT). 
Two volumes (0.5 or 1.5 ml) were tested in the vaginal compartment and two volumes (1 or 
4 ml) were applied in the rectum. Gel IQB4012 is similar to IQB3002 evaluated in our 
previous study in that it is formulated for dual application in the vagina and rectum (Table 
1). In addition to 1% IQP-0528, IQB4012 also contains 1% of the NRTI tenofovir (TFV).
Materials and methods
Drug and product formulation
IQB4012 was manufactured by ImQuest BioSciences (Frederick, MD). The gel (Table 1) 
contains 1% (w/w) IQP-0528 [49–51], 1% (w/w) TFV, 10 mM sodium phosphate solution in 
sterile molecular grade water (93.15% w/w), glycerol (2.5% w/w), methylparaben (0.2% 
w/w), propyl paraben (0.05% w/w), hydroxyethyl cellulose (1% w/w), carbopol (1% w/w), 
EDTA (0.05% w/w), DL-lactic acid (0.05% w/w) [48]. It has a pH of 6.00, osmolality of 360 
mOsm/kg and viscosity @ 1 s−1 = 128.7 Pa s. The release properties of IQP-0528 and TFV 
from the gel into a liquid sink (Franz Cell) are 53.93 and 82.51 μg/cm 3h, respectively, with 
tissue permeability of 118.36 and 206.86 μg/cm3, respectively. The product was stored at 
room temperature (25 °C) in a dark, moisture-free environment until use.
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Pigtailed macaques and study design
All procedures in this study were approved by the Centers for Disease Control and 
Prevention IACUC (Institutional Animal Care and Use Committee). Animals were housed 
under approved biosafety level 2 containment conditions at the Centers for Disease Control 
and Prevention (CDC), and their diet, care, and maintenance conformed to “Guide for the 
Care and Use of Laboratory Animals” guidelines [52]. Six sexually mature, naive female 
pigtailed macaques (PT) with an average body mass of 8.7 kg were utilized in this study. All 
PT were anesthetized prior to procedures using 10 mg/kg ketamine mixture intramuscularly, 
or other approved anesthetic such as Telazol, 2–6 mg/kg intramuscularly, as determined by 
CDC Animal Resources Branch (ARB) standard operating protocol and ARB staff including 
the attending veterinarian. Ketamine and Telazol were supplied by the staff pharmacist in the 
Animal Resources Branch in accordance with CDC guidelines. For vaginal PK experiments, 
each PT received 0.5 ml or 1.5 ml of IQB4012 gel following anesthesia. Rationale for 
dosing (gel volume) was based on relative scaling of the size of the macaque female 
reproductive tract relative to humans. The upper volume is therefore equivalent by volume to 
a human dose of 4 mL. Gel was delivered into the posterior vagina, near the cervix, using a 
sterile 10-ml syringe attached to a sterile gastric feeding tube (size, 5 or 9 French; 7 to 8 cm 
in length). Syringes were weighed pre and post gel application to verify weight and volume 
of gel delivered. Animals were maintained recumbent under anesthesia with the pelvis 
slightly elevated for 30 min to minimize gel leakage. Animals were placed in two groups of 
three each. One group received 0.5 mL of IQB4012, while the other group received 1.5 mL 
IQB4012 once weekly for 4 consecutive weeks. After a 2-week rest period, the doses of the 
groups were then switched for another 4 weeks so that all six macaques received each dose 
four times. The data presented are therefore a summary of 24 applications of 0.5 and 1.5 mL 
of IQB4012.
For rectal PK experiments, a similar syringe apparatus was used to deliver 1 or 4 ml of 
IQB4012 into the rectum 2 in. past the sphincter of each PT after performing a rectal wash 
with 10 ml physiological saline. As with the vaginal PK study, the same crossover design 
was used with rectal gel application performed once weekly for 4 weeks with a 2-week rest 
period before the crossover and an additional 4 weeks of application. The rectal PK 
experiments were initiated several weeks after the vaginal PK study, to allow for a suitable 
wash-out period.
Specimen collections
For the vaginal gel application experiments, specimens collected for PK assessments 
included blood plasma, vaginal and rectal 3-mm punch biopsy specimens (n = 3 punch 
biopsies per site), vaginal secretions (multiswab device fitted with Weck-Cel® sponges, 
collected proximally and distally relative to the cervix), and rectal secretions approximately 
5 cm into the rectum (Weck-Cel® spears). Spears and sponges were weighed before and 
after specimen collection. Vaginal pH was determined by collecting a swab of vaginal fluid 
and rolling it on a pH colorimetric indicator strip (EMD Millipore). Blood and swabs were 
collected immediately prior to (0 h) and at specific time intervals (2 h, 4 h, and 24 h) after 
IQB4012 application (Table 2). Tissue biopsies were collected at 4 h and 24 h only. Identical 
time points and specimens were used for collection of blood plasma, rectal fluids, and rectal 
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biopsies following rectal application of IQB4012 (Table 2). Blood was obtained via the 
saphenous or femoral veins using a 21–22 gauge vacutainer needle set-up into cell 
preparatory tubes (CPTs) and processed to obtain plasma and peripheral blood mononuclear 
cells. All specimens were collected, processed, and stored at − 70 °C until drug analysis as 
detailed previously [45].
Measurement of IQP-0528 and TFV concentrations
Vaginal fluids in individual multiswab Weck-Cel® sponges (two proximal and two distal per 
animal per time point each week), and rectal fluids in individual Weck-Cel spears (two 
spears per animal per time point each week) were analyzed for IQP-0528 and TFV levels. 
Each week, biopsy samples that included three punches from vaginal tissues (one proximal, 
one medial, one distal per time point per animal), and two punches from rectal tissues 
collected approximately 5 cm into the rectum were analyzed per animal per time point. 
Unlike the active form of TFV, IQP-0528 is rapidly transported bi-directionally across the 
cell membrane and is not restricted within the cell, and so tissues were not washed prior to 
analysis to avoid drug loss [46]. For plasma, 100 μl aliquots per animal per time point from 
each week were analyzed. The concentrations of IQP-0528 and TFV in the biological 
samples were determined based on a previously described liquid chromatography-tandem 
mass spectrometry (LC-MS) method [45, 53, 54]. The minimum level at which quantitative 
results could be obtained, the lower limit of quantitation (LLOQ), is ten times the standard 
deviation of injections at the lowest concentration which were statistically different from 
blank injections using a 99% confidence interval. The LLOQ of IQP-0528 for tissues, 
vaginal or rectal fluids, and plasma were determined to be 10 ng/sample for biopsies and 10 
ng/ml for fluids. Vaginal fluid and tissue densities of 1.0 g/ml were used to convert weight to 
volume concentrations of IQP-0528 and TFV (ng/g of fluid or tissue). Reported 
concentrations in vaginal secretions were corrected to account for sponge net weight and 
dilution factors. Data for rectal fluids are reported as ng/ml of spear eluate.
Statistical analyses
Data shown are medians with minimum and maximum values unless indicated otherwise. To 
analyze differences in IQP-0528 and TFV levels across multiple time points and animals, 
one-way analyses of variance (ANOVA) were applied, with Dunns post-test analysis. 
Significant paired data sets (p < 0.05) were further analyzed ad-hoc using the Wilcoxon 
matched-pairs signed-rank t test. Analyses were performed using GraphPad Prism 
(GraphPad Software, Inc., La Jolla, CA).
Results
Vaginal application of IQB4012
Specimens collected over a 24-h period after 0.5 ml gel application showed that median 
IQP-0528 concentrations in vaginal tissues and vaginal fluids at 4 h (open black boxes, Fig. 
1a, b; Table 3) were of the order of 105 ng/g (95,000–290,086 ng/g) and 106 ng/ml 
(2,038,462−6,758,116 ng/ml), respectively. These were followed by a statistically significant 
(p < 0.0001) one log decrease in vaginal fluids at 24 h (257,071–328,205 ng/ml). IQP-0528 
levels in vaginal fluids at 2 h were similar to those observed at 4 h. The graphs (Fig. 1a, b) 
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illustrate pooled data from proximal, medial, and distal sites relative to the cervix, with 
Table 3 listing median concentrations at each of those sites. Data were grouped for analysis 
(Fig. 1a, b) as there was no significant difference in IQP-0528 concentrations across those 
sites at matched time points. Interestingly, application of 1.5 ml gel (open gray boxes, Fig. 
1a, b; Table 3) yielded similar results in vaginal tissues and fluids, with IQP-0528 
concentrations being in the same range as that following 0.5 ml gel treatment (open black 
boxes, Fig. 1a, b; Table 3). Slight amounts of gel were observed to be present at the 2-h 
collection, but gel was not present in the vast majority of the 4-h samples. Low 
concentrations of IQP-0528 were detected in rectal fluids (Fig. 1c and Table 3) following 
vaginal application of either volume of IQB4012, with median levels being in the range of 
101–103 ng/ml over 24 h (20–1258 ng/ml). A significant difference between the two gel 
volumes was noted for IQP-0528 concentrations in rectal fluids at 2 h (open black and open 
gray boxes, Fig. 1c), but not at later time points. Analysis of rectal tissue biopsies revealed 
IQP-0528 levels below LLOQ (data not shown).
Similar to the trends observed for IQP-0528 PK, there were no significant differences in 
TFV concentrations across all time points when comparing applications of 0.5 and 1.5 ml 
gel in the vaginal canal. Median levels of TFV were 1–2 logs lower than IQP-0528 
concentrations at matched time points over the 24-h period. They were 103–104 ng/g in 
vaginal tissues (4486–13,367 ng/g for 0.5 ml gel; 10,181–35,081 ng/g for 1.5 ml gel) and 
104–105 ng/ml in vaginal secretions (124,304–132,458 ng/ml for 0.5 ml gel; 54,269–
152,548 ng/ml for 1.5 ml gel) at 4 h, followed by a negligible decrease in concentrations at 
24 h (striped black and striped gray boxes, Fig. 1a, b; Table 3). Similar to IQP-0528 levels in 
the rectum, median concentrations of TFV in rectal secretions were low and not always 
detectable and did not exceed 200 ng/ml over 24 h (striped black and striped gray boxes, 
Fig. 1c; Table 3). Concentrations in rectal biopsy tissues were below the LLOQ (1 ng/
sample, data not shown). In summary, these data collectively show that a twofold difference 
in gel volume (0.5 versus 1.5 ml) did not have a significant impact on the PK of either 
IQP-0528 or TFV in the vaginal compartment. Plasma concentrations of both compounds 
were below the LLOQ (10 ng/ml, data not shown).
Rectal application of IQB4012
After a wash-out period following the vaginal PK study, rectal PK experiments were 
conducted in the same macaques. Either 1 or 4 ml of IQB4012 gel was applied rectally. 
Rectal spears were collected at 2, 4, and 24 h, and rectal pinch biopsies were collected at 4 
and 24 h, which are time points identical to those considered in the vaginal PK study. 
Application of 1 ml IQB4012 gel yielded median IQP-0528 concentrations in the two-log 
range, 103–105 ng/ml in rectal fluids. There was a statistically significant (p < 0.0001) 
decrease from 93,375 ng/ml at 2 h to 2975 ng/ml at 24 h (open black bars, Fig. 2a; Table 4). 
Following application of 4 ml of gel, similar IQP-0528 concentrations were observed in 
rectal fluids over the 24-h period (open gray bars, Fig. 2a; Table 4). Interestingly, despite the 
relatively high IQP-0528 concentrations present in rectal fluids, approximately half of the 
rectal tissue samples analyzed were found to have IQP-0528 concentrations below the 
LLOQ. This was primarily found in the low volume group, where nearly two-thirds of rectal 
biopsies from animals treated with 1 ml had undetectable levels of IQP-0528. Tissue 
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samples with detectable concentrations were in the range of 102–103 ng/g for both gel 
volumes tested (black open bars and gray open bars, Fig. 2b; Table 4), and there was no 
significant difference in IQP-0528 concentrations between the two gel volumes at matched 
time points.
Analysis of TFV levels in rectal fluids showed similar patterns to those for IQP-0528. 
Volumes of 1 ml (striped black bars, Fig. 2a; Table 4) and 4 ml (striped gray bars, Fig. 2a; 
Table 4) yielded comparable drug concentrations at matched time points. Specifically, 
median fluid TFV concentrations were on the order of 103 ng/ml (3230 ng/ml for 1 ml gel; 
5065 ng/ml for 4 ml gel) at 2 h, and 102 ng/ml at 4 h (705 ng/ml for 1 ml gel; 864 ng/ml for 
4 ml gel) and 24 h (132 ng/ml for 1 ml gel; 277 ng/ml for 4 ml gel). It should be noted that 
approximately two-thirds of rectal fluid samples from the low volume group yielded TFV 
levels below the LLOQ. The levels of TFV and TFV-diphosphate (TFV-DP), the active 
intracellular form of TFV, in approximately half of the rectal tissue samples from animals 
treated with 1 ml gel were also below the LLOQ, with detectable concentrations (Table 4) 
being at or near the magnitude of 102 ng/g at 4 h (811 ng/g TFV; 176 ng/g TFV-DP) and 24 
h (659 ng/g TFV; 70 ng/g TFV-DP). Median concentrations of TFVand TFV-DP in rectal 
tissues from the 4-ml gel volume group (striped gray bars and dotted gray bars, Fig. 2b; 
Table 4) were not significantly different from the low volume group at matched time points. 
Median TFV and TFV-DP concentrations were near 102–103 ng/g or less at 4 h (393 ng/g 
TFV; 47 ng/g TFV-DP) and 24 h (1,411 ng/g TFV; 81 ng/g TFV-DP). To summarize, the PK 
results showed that IQP-0528 and TFV/TFV-DP concentrations in the rectum were each 
comparable between the 1 and 4 ml gel groups over a 24-h period, with a notable number of 
the rectal specimens yielding values below LLOQ (10 ng/sample), particularly for TFVand 
the low volume (1 ml) group. Systemic drug absorption was not apparent after rectal 
application of IQB4012, as levels of both drugs were below the LLOQ (10 ng/ml) in blood 
plasma (data not shown).
Discussion
Microbicide gel volume is one of many factors that influence user acceptability, but its 
impact on in vivo PK has not been fully elucidated. The impact of gel volume may differ 
among microbicide drugs with different physicochemical properties and may be different for 
vaginal versus rectal gel application. The present study addressed three factors; gel volume, 
drug and target compartment. The test gel, IQB4012, has been developed specifically to 
address the need for a safe and effective rectal microbicide product, particularly given the 
prevalence of receptive anal intercourse in heterosexual populations and its impact on HIV 
transmission [55–64]. Because IQB4012 is formulated for safe application both in the 
vagina and rectum [47, 48], convenience to user(s) is promoted, bypassing the need for 
separate products for vaginal and rectal use and potentially improving product acceptability 
and adherence. This formulation was engineered as an improvement on its predecessor, 
IQB3002, with rheological properties designed not simply to promote good initial spreading 
along the vaginal and rectal canals, but improved retention after initial application (Table 1).
MRI-based in vivo imaging studies of two volumes (2.5 versus 3.5 ml) of up to seven 
different microbicide gels and personal lubricants in women showed that there were no 
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statistically significant differences between the volumes tested [65]. Recently, an optical 
imaging study comparing vaginal applications of 2 versus 4 ml of the HEC gel used as a 
placebo in microbicide trials, found differences in coating thickness but not extent of coating 
along the canal; computational modeling inferences from those data suggested small 
differences in mucosal drug delivery between the two volumes [66]. However, it is important 
to note that besides volume and gel composition, host factors such as ambulation, presence 
of semen, and local dilution of gel (estimated to range 10–30%) due to ambient fluid in the 
vaginal compartment, also impact a gel’s rheological properties and consequent deployment 
and drug delivery [67–71].
Co-formulation of IQB4012 with both IQP-0528 and TFV provides two drugs with 
contrasting physicochemical properties: IQB4012 is hydrophobic and lipophilic, while TFV 
is relatively hydrophilic. Those distinctions impact the relative transport rates of the drugs 
out from the gel and into and through the mucosal tissue. These two drugs have exhibited 
additive to synergistic activity that is concentration dependent when tested with primary 
HIV-1 isolates in vitro [72]. IQP-0528 diffuses bi-directionally across cell membranes, 
whereas TFV is phosphorylated within cells and retained with a long half-life [46, 73, 74]. 
This allows for one of the active drugs to be readily available to trafficking cells. These 
differing characteristics may well be advantageous for better protection when the two drugs 
are delivered together. The susceptible cells in the mucosa are loaded with TFV-DP, and this 
has been a good correlate of protection in macaque efficacy studies with gels and 
intravaginal rings [73, 75]. This formulation advantage may be similar to what has been 
observed for the combination of TFVand FTC in macaque efficacy studies where the PK of 
the two compounds lead to a more broad window of protective efficacy than a single drug 
alone [76].
Results from this study show that the concentrations of IQP-0528 measured in fluids from 
the vaginal compartment after vaginal application were 5–6 logs higher than the reported 
EC50/IC50 value for IQP-0528 [46, 47, 49–51, 73, 77] up to 24 h post gel application, and 
were 1–3 logs higher than the EC50 in rectal fluids (Table 3, ratio of measured/EC50). In 
contrast, the measured drug/EC50 ratio for TFV when applied vaginally was substantially 
lower than (range 26–1009) reflecting the difference in potency of the two drugs (Table 3). 
A very similar trend was evident when the gel was applied rectally (Table 3), with IQP-0528 
ratios being 3–5 logs higher than the EC50 and the TFV ratios being substantially lower in 
rectal fluids (range 0.12–7.35).
Results showed no significant differences between applied gel volumes in fluid and tissue 
levels for both IQP-0528 and for TFV in the vagina and in the rectum. Further, rectal tissue 
TFV-DP levels did not differ between volumes when applied rectally. Differences were not 
detected in tissue concentrations of both drugs sampled at proximal versus medial versus 
distal locations along the vaginal canal, i.e., their longitudinal drug delivery was uniform. 
Furthermore, bi-directional dosing was observed as shown by presence of drug, albeit at low 
concentrations, in rectal fluids following vaginal application of both 0.5 and 1.5 ml 
IQB4012. Similar effects were observed when comparing PK data for the two volumes (1 
versus 4 ml) tested in the rectal PK study, although the majority of specimens collected from 
the low volume (1 ml) group had undetectable levels of IQP-0528 and TFV. These results 
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were somewhat surprising given that the total drug in the lower volumes was one fourth of 
that in the higher volumes. However, the range of measured values was such that a fourfold 
difference would be difficult to detect.
We emphasize, however, that IQP-0528 (and other microbicides, more generally) delivery 
and potency within the rectal compartment may be different from those for the vagina. Many 
factors could contribute to this, including: compartment size and openness; composition of 
luminal fluids and luminal drug clearance processes; mucosal tissue structure and cell types, 
including target cells and their distributions; mucosal tissue permeability; and pH and the 
microbiome. In addition to differences in length and mucosal surface area, the mucosal 
structures of the two organs are different. The vagina has a multilayer, non-secretory, 
stratified squamous epithelium with thickness of hundreds of micrometers. Infectible host 
cells populate the lamina propria below it, which is primarily connective tissue. The rectal 
mucosa is characterized by a single layer of mucus-secreting columnar epithelial cells 
arranged in rugae that extend millimeters down into the mucosa; the lamina propria wraps 
around the rugae, and extends downward, containing pockets of lipids within its connective 
tissue. These qualitatively different environments present different permeabilities to 
migrating molecules, and virions. Vaginalrectal contrasts in TFV delivery have been 
predicted by a deterministic computational PK model [78].
The threshold for minimum volumes may be higher for the rectum than the vaginal canal 
because of physiological and anatomical differences. If potentially efficacious drug levels 
can be achieved with lower gel volumes as suggested by these results, a “less is more” 
approach presents a feasible option that could help improve user perceptibility and 
experience of this gel, thereby encouraging product adherence. However, user sensory 
perceptions are multifaceted and what might be acceptable to some may not be to others. 
The data reported herein are only intended to provide information about the viability of 
additional choices. Further investigation is needed, particularly to determine the optimal 
volume for use in the rectal compartment. There is currently no consensus for rectal 
microbicide gel volumes, unlike the relatively narrow range used for vaginal gels (3.5–4 ml 
in clinical trials); a wide range (1.5–35 ml) of volumes has been tested for rectal use thus far. 
Other gel formulation properties that govern spreading and absorption may have to be 
adjusted accordingly to account for volume, especially when user-dependent characteristics 
come into play. Indeed, a caveat of the current study is that it is not designed to factor in 
ambulation due to necessary sedation of macaques during experiments. Thus, its effect on 
gel spreading and subsequent PK relative to gel volume remains to be elucidated. In 
addition, we also cleansed the area with a 10-ml saline wash prior to insertion. Cleansing 
prior to RAI is common, but not always the case. The IQB4012 gel formulation has 
demonstrated good safety profiles in human ectocervical and colorectal tissue explants, 
while also effectively inhibiting HIV-1 replication in these tissue models at concentrations as 
low as 10 μM (A. Ham et al., unpublished data). The findings from the in vivo study 
described herein build upon these promising characteristics of IQB4012. They complement 
computational PK models and imaging studies and provide further insight on ARV PK in the 
context of gel volume. This, in turn, can inform microbicide gel applications in clinical trial 
settings.
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In summary, our results collectively show that the dual compartment IQB4012 gel is capable 
of delivering both IQP-0528 and TFV in vaginal and rectal tissues to levels well above 
concentrations that are inhibitory to HIV-1 in vitro. Lowering gel volumes by a factor of 3–
4, and a corresponding reduction of total drug, did not appear to significantly impact PK of 
IQP-0528 and TFVin the vaginal and rectal compartments. Additional studies using a 
reduction in total drug of tenfold or more might result in a significant difference in drug 
levels, but a reduction of tenfold in volume was beyond the scope of this study. Importantly, 
our findings are consistent with our previous report evaluating vaginal application of 1.5 ml 
IQB3002 gel formulation, and also align with optical imaging and computational modeling 
studies that showed pharmacologically small effects when varying gel volume [79]. These 
findings provide relevant information for clinical trials of microbicide gels, and lay a 
foundation for future studies that include investigating the impact of lower gel volumes on 
efficacy.
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Fig. 1. 
Analysis of IQP-0528 (open) and TFV (striped) levels in a vaginal tissues, b vaginal fluids, 
and c rectal fluids from N = 6 macaques treated vaginally with 0.5 (black) or 1.5 ml (gray) 
IQB-4012 gel. Results shown for vaginal samples include pooled data from proximal, 
medial, and distal sites. Concentrations at each of these sites are listed in Table 2. One-way 
ANOVA test with Dunns post-test analysis was performed. Significant paired data sets (p < 
0.05) were further analyzed ad-hoc using Wilcoxon matched-pairs signed-rank t test, and 
yielded p values < 0.0001 where indicated (*)
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Fig. 2. 
Analysis of IQP-0528 (open), TFV (striped), and TFV-DP (dotted) levels in a rectal fluids 
and b rectal tissues from N = 6 macaques following rectal application of 1 (black) or 4 ml 
(gray) IQB-4012 gel. Concentrations at each of these sites are detailed in Table 3. One-way 
ANOVA test with Dunns post-test analysis was performed. Significant paired data sets (p < 
0.05) were further analyzed ad-hoc using Wilcoxon matched-pairs signed-rank t test, and 
yielded EC50 < 0.0001 where indicated (*)
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Table 1
DuoGel formulations
Ingredient (w/w, %) 3002 4012
Tenofovir / 1.00
IQP-0528 1.00 1.00
Phosphate buffer 93.90 93.15
Glycerin 2.50 2.50
Hydroxyethyl cellulose 2.10 1.00
Carbopol 0.25 1.00
Methylparaben 0.20 0.20
Propylparaben 0.05 0.05
EDTA / 0.05
Lactic acid / 0.05
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Table 2
Outline of study design and specimen collections. For the vaginal PK study, female pigtailed macaques (N = 
6) were treated with 0.5 or 1.5 ml IQB4012 that was applied in the posterior vagina, proximal to the cervix. 
For the rectal PK study, 1 or 4 ml IQB4012 was applied in the rectum of N = 6 female pigtailed macaques. 
Specimens indicated were collected immediately before (0 h) and at 2, 4, and 24 h after each weekly gel 
application
Sample 0 h* 2 h 4 h 24 h
Blooda (vaginal and rectal PK) X X X X
Vaginal multiswabb (vaginal PK) X X X X
Rectal spearsc (vaginal and rectal PK) X X X X
Vaginal pinch biopsiesd (vaginal PK) - - X X
Rectal pinch biopsiese (vaginal and rectal PK) - - X X
Vaginal pHf (vaginal PK) X X X X
a2-ml CPT tubes
bVaginal multiswab device loaded with eight Weck-Cel sponges; four proximal and four distal
c
Two rectal wicks/animal/time point
dVAGINAL: three pinch biopsies/animal/time point (one prox, one med, one dist)
e
RECTAL: two pinch biopsies/animal/time point
fVaginal pH: pH indicator strips
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